Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

ObjectivesIn our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment. We conducted this extension study to investigate whether the advantage...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Yasuaki Hirooka, Yuji Nozaki, Saki Okuda, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2021-09-01
Reeks:	Frontiers in Endocrinology
Onderwerpen:	bone mineral density teriparatide denosumab bisphosphonate glucocorticoid-induced osteoporosis
Online toegang:	https://www.frontiersin.org/articles/10.3389/fendo.2021.753185/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!